Aicardi-Goutières syndrome is a rare inherited condition where the body’s immune system mistakenly attacks its own brain tissue, causing inflammation that can lead to lasting neurological challenges. Treatment focuses on managing symptoms, slowing disease progression, and supporting children and families through multiple medical needs, while researchers explore promising new therapies that may one day change the course of this challenging condition.

Understanding Treatment Goals in Aicardi-Goutières Syndrome

When a child receives a diagnosis of Aicardi-Goutières syndrome, families enter a complex medical journey where treatment decisions depend heavily on when symptoms appear and how severe they become. The main goals of treatment center on controlling symptoms, reducing inflammation in the brain and other organs, preventing complications, and improving the child’s quality of life as much as possible. Because AGS affects children differently—some severely from birth and others more mildly after several months—treatment plans must be tailored to each individual child’s needs and stage of disease.^[1]

Currently, medical societies recognize that there is no cure for AGS, and standard treatments aim to address specific problems as they arise rather than stopping the disease process itself. This means families work with multiple specialists to manage feeding difficulties, seizures, muscle stiffness, skin problems, and developmental support. However, the medical community has made important progress in understanding what causes AGS at the molecular level, which has opened doors to new research into therapies that might actually target the underlying immune system dysfunction. Clinical trials are now testing innovative drugs that could potentially slow or even halt the inflammatory damage that characterizes this condition.^[8]

The treatment approach also depends on whether a child has early-onset or later-onset AGS. Children born with signs of the disease often face more severe challenges and require intensive medical support from the beginning, while those who develop symptoms after a few months of normal development may experience a somewhat milder course, though they still face significant long-term difficulties. In both cases, treatment teams include neurologists, immunologists, physical and occupational therapists, nutritionists, and other specialists who work together to support the whole family, not just the affected child.^[3]

Standard Treatment Approaches

The backbone of AGS treatment consists of managing individual symptoms and preventing complications through supportive care. Because the disease affects multiple body systems, standard treatment involves a range of interventions that address specific problems as they develop. There is no single medication that treats AGS itself in conventional practice, so doctors focus on making children as comfortable as possible and supporting their development despite neurological damage.^[6]

For children who experience seizures—a common problem in AGS—doctors prescribe anticonvulsant medications (also called anti-seizure drugs). These medications work by calming overactive electrical signals in the brain. The specific drug chosen depends on the type of seizures a child has and how well they respond to treatment. Some children need only one medication, while others require a combination of drugs to control seizures effectively. Doctors monitor blood levels of these medications and adjust doses as children grow to maintain the right balance between seizure control and side effects.^[1]

Muscle problems are another major concern. Many children with AGS develop spasticity, where muscles become stiff and tight, making movement difficult and sometimes painful. Physical therapy is essential—therapists work with children regularly to maintain flexibility and prevent joints from becoming locked in abnormal positions. Some children benefit from medications that relax muscles, such as baclofen or diazepam, which work by reducing signals from the nervous system that cause muscles to contract. In more severe cases, doctors may recommend injections of botulinum toxin (Botox) directly into specific muscles to temporarily reduce spasticity in targeted areas, allowing for better positioning and comfort.^[3]

Feeding difficulties plague many infants and children with AGS, especially in early-onset forms. Problems with swallowing, poor muscle tone around the mouth, and general irritability can make eating by mouth difficult or impossible. Gastrostomy tube placement—a surgical procedure that creates an opening in the abdomen for feeding directly into the stomach—becomes necessary for many children to ensure adequate nutrition and hydration. This intervention prevents aspiration (food or liquid entering the lungs) and allows families to provide proper nutrition even when oral feeding is unsafe or insufficient.^[3]

Respiratory care is critically important because weak muscles and poor coordination can affect breathing. Some children need regular chest physiotherapy, where therapists or parents perform techniques to help clear mucus from the lungs and prevent pneumonia. In more severe cases, children may require breathing support through various devices, ranging from supplemental oxygen to mechanical ventilation. Families learn to monitor for signs of respiratory distress and work closely with pulmonologists to maintain lung health.^[6]

For the characteristic skin problems called chilblains—painful, itchy, red swellings on fingers, toes, ears, and nose that worsen in cold weather—treatment involves protecting affected areas from cold exposure. Families keep children warm, dress them in layers, and use gentle moisturizers. In some cases, medications that improve blood flow to small vessels, such as nifedipine (a calcium channel blocker), may help reduce chilblain severity. However, these medications must be used carefully in children and require close monitoring.^[2]

Vision problems, including glaucoma (increased pressure inside the eye) and cortical blindness (vision loss due to brain damage rather than eye problems), require ophthalmology involvement. Children with glaucoma may need eye drops or even surgery to reduce pressure and prevent further damage to the optic nerve. Regular eye examinations help catch problems early when interventions are most effective.^[4]

The duration of these standard treatments typically extends throughout childhood and often into adulthood, as AGS is a lifelong condition. Some symptoms may stabilize over time, particularly in later-onset forms where the initial inflammatory phase settles after several months. However, neurological damage that has already occurred is permanent, so supportive therapies and symptom management continue indefinitely. Regular follow-up with the treatment team allows adjustments as children grow and their needs change.^[8]

Side effects from standard treatments vary depending on the specific interventions. Anticonvulsant medications can cause drowsiness, behavior changes, or effects on liver function that require monitoring through blood tests. Muscle relaxants may cause excessive sedation or weakness. Gastrostomy tubes carry risks of infection at the insertion site or tube displacement. Each treatment decision involves weighing benefits against potential risks, and families work closely with doctors to find the best balance for their individual child.^[12]

Innovative Therapies in Clinical Trials

The discovery of specific genes responsible for AGS and the understanding that the disease involves excessive production of interferon—a chemical messenger in the immune system—has revolutionized thinking about potential treatments. Rather than just managing symptoms, researchers now focus on developing therapies that target the root cause of inflammation. Several promising approaches are currently being studied in clinical trials or are in earlier stages of research.^[8]

One of the most promising strategies involves drugs called JAK inhibitors (Janus kinase inhibitors). These medications work by blocking the signaling pathway that interferon uses to trigger inflammation inside cells. When interferon attaches to receptors on cell surfaces, it normally activates JAK proteins, which then send signals into the cell nucleus to turn on inflammatory genes. By blocking JAK proteins, these drugs can reduce the inflammatory response even when interferon levels remain high.^[9]

Ruxolitinib is a JAK1/JAK2 inhibitor that has been used in several children with AGS. This medication was originally developed and approved for certain blood disorders and cancers in adults, but doctors have used it “off-label” in AGS based on the understanding of disease mechanisms. Clinical reports and small studies have shown that some children treated with ruxolitinib experienced improvement in skin rashes, reduced inflammatory markers in blood tests, and better liver function. Some families also reported that their children seemed to have developmental gains, though this is difficult to measure precisely. However, results have been mixed—not all children respond equally well, and some continued to have uncontrolled inflammation despite treatment.^[13]

The experience with JAK inhibitors has taught researchers important lessons. While these drugs can be helpful for certain symptoms, particularly skin problems and some inflammatory markers, they may not completely shut down all aspects of AGS inflammation. One case report described a child with AGS type 7 (caused by mutations in the IFIH1 gene) who continued to have elevated inflammatory markers despite ruxolitinib treatment. When doctors added tocilizumab—a different drug that blocks interleukin-6, another inflammatory molecule—the inflammation finally came under control. This suggests that the inflammatory process in AGS may involve multiple pathways, not just interferon signaling, and that combination approaches might work better than single drugs.^[13]

Another experimental approach involves reverse transcriptase inhibitors (RTIs), medications commonly used to treat HIV infection. The rationale behind this strategy comes from the “retroelement hypothesis,” which suggests that in some forms of AGS, accumulated DNA in cells may come from retroelements—pieces of genetic material that normally stay quiet but can become active. Reverse transcriptase inhibitors prevent these retroelements from making copies of themselves. An open-label pilot study tested a combination of three RTIs (abacavir, zidovudine, and lamivudine) in children with AGS caused by mutations in TREX1, RNASEH2A, RNASEH2B, or SAMHD1 genes. Unfortunately, this trial showed no obvious clinical benefit, suggesting either that the retroelement hypothesis doesn’t fully explain AGS pathology or that these particular drugs couldn’t effectively reach the problem areas in the brain.^[8]

A groundbreaking new approach comes from researchers at the University of Sydney who developed an RNA-targeted therapy using antisense oligonucleotides. These are specially designed pieces of genetic material that bind to the messenger RNA for the interferon alpha receptor, effectively preventing cells from making this receptor protein. Without receptors, cells cannot respond to interferon, even if it remains in circulation. In mouse models of AGS, this therapy showed remarkable results—it reduced neuroinflammation, decreased neuronal damage, and restored the integrity of the blood-brain barrier (the protective barrier that normally keeps harmful substances out of brain tissue). This research, conducted in collaboration with Ionis Pharmaceuticals and Biogen, represents a significant advancement because it shows that targeted therapy can halt disease progression and potentially reverse some damage. The findings were published in The Journal of Clinical Investigation and offer hope for future human trials.^[11]

The phases of clinical trials follow a standard progression. Phase I trials focus primarily on safety—researchers give the drug to a small number of participants to see what dose can be tolerated and what side effects occur. Phase II trials involve more participants and begin to assess whether the drug actually works (efficacy) while continuing to monitor safety. Phase III trials are larger studies that compare the new treatment to current standard care or placebo to definitively prove benefit. Many AGS therapies are currently in Phase I or Phase II stages, meaning researchers are still learning about safety and optimal dosing.^[9]

Clinical trials for AGS and related interferonopathies have been conducted or are planned at major medical centers, particularly in the United States, Europe, and other developed regions. Children’s Hospital of Philadelphia, Children’s National Medical Center in Washington DC, and centers in the United Kingdom have been leaders in AGS research and treatment. International collaboration through networks allows researchers to pool data from multiple centers, which is essential for rare diseases where individual hospitals may see only a handful of patients.^[15]

Eligibility for clinical trials typically requires confirmation of AGS through genetic testing showing mutations in one of the known AGS genes. Some trials may be specific to certain genetic subtypes—for example, a trial might enroll only children with TREX1 mutations or only those with IFIH1 mutations, since different mutations may respond differently to treatments. Age restrictions are common, as some trials focus on very young children who are early in their disease course, while others may include older children or even adults with later-onset forms. Disease severity also matters—some trials seek participants with active inflammation who might show clearer responses, while others may include children at any disease stage.^[9]

The mechanism of action for emerging therapies varies. JAK inhibitors work inside cells to block interferon signaling pathways. Antisense oligonucleotides prevent cells from making interferon receptors by targeting the messenger RNA before it can be translated into protein. Other strategies under investigation include antibodies that bind directly to interferon proteins in the bloodstream, neutralizing them before they reach cells. Some researchers are exploring whether existing drugs used for other autoimmune conditions, such as those targeting other inflammatory cytokines, might have a role in AGS treatment.^[12]

Preliminary results from small studies and case reports have shown encouraging signs. Some children treated with JAK inhibitors have had visible improvement in skin rashes within weeks to months, blood tests showing reduced inflammatory markers, and family reports of improved alertness or social engagement. However, these observations come from uncontrolled studies without comparison groups, making it difficult to know how much improvement comes from the medication versus natural disease variability. The safety profile of JAK inhibitors in children with AGS has generally been acceptable, though concerns include potential increased infection risk (since these drugs suppress immune function) and unknown long-term effects on growth and development.^[9]

Most common treatment methods

• Anticonvulsant medications
  • Drugs that reduce abnormal electrical activity in the brain to control seizures, which affect many children with AGS
  • Require regular monitoring and dose adjustments as children grow
  • May cause side effects like drowsiness or liver function changes
• Physical and occupational therapy
  • Regular sessions to maintain flexibility, prevent joint contractures, and support motor development
  • Occupational therapy helps with daily activities and adaptive equipment needs
  • Lifelong therapy is typically needed as part of comprehensive care
• Muscle relaxant medications
  • Drugs like baclofen or diazepam that reduce muscle stiffness and spasticity
  • Botulinum toxin injections into specific muscles for targeted spasticity relief
  • Help improve positioning, comfort, and ability to participate in therapy
• Nutritional support and gastrostomy feeding
  • Surgical placement of feeding tubes when oral feeding is unsafe or insufficient
  • Ensures adequate nutrition and prevents aspiration pneumonia
  • Requires family training on tube care and feeding techniques
• Respiratory care
  • Chest physiotherapy to clear airways and prevent lung infections
  • Supplemental oxygen or mechanical ventilation for severe cases
  • Regular monitoring by pulmonology specialists
• JAK inhibitors (experimental)
  • Ruxolitinib and similar drugs that block interferon signaling pathways
  • Used in clinical trials or off-label based on case reports showing benefit
  • May improve skin rashes, inflammatory markers, and some symptoms
  • Safety and long-term effects in children still being studied
• Other immunomodulatory approaches (experimental)
  • Tocilizumab and other drugs targeting different inflammatory pathways
  • Antisense oligonucleotides targeting interferon receptor production
  • Reverse transcriptase inhibitors tested with limited success
  • Currently available primarily through research studies
• Supportive symptom management
  • Medications for pain, irritability, and sleep disturbances
  • Treatment of vision problems including glaucoma
  • Protection from cold exposure to manage chilblains
  • Regular monitoring for complications affecting multiple organ systems